[Study of pefloxacin concentration in blood and sputum in the aged pneumonia patients with impairment of renal function].
OBJECTIVE
To study the drug concentration in blood and sputum, clinical effect and drug toxicity of pefloxacin in the aged pneumonia patients with different degree of impairment of renal function.


METHODS
The patients were divided into four groups according to the impairment of renal functions pefloxacin 400 mg/12 h venous inflow, period of treatment is 10 days. Clinical manifestation and experimental index were registered; the drug concentration in blood and sputum was measured with biochemical technique, then compared and analyzed.


RESULTS
The drug concentration in blood and sputum in four groups differed from the degree of the impairment of renal function. The concentration of drug in blood and sputum of the normal renal function was close to that in the low-grade impairment of renal function. Their clinical effective ratios were 83%, 80%, bacterium cleanup ratio was 86%. The difference of drug concentration in blood and sputum in the severe impairment of renal function was greater than that in the moderate renal function group, their clinical effective ratios were 66%, 53%, bacterial cleanup ratios were 57%, 36%, adverse reaction was growing along with degree of impairment of renal function. This drug has renal toxicity for moderate and severe impairment of renal function.


CONCLUSIONS
In case of moderate impairment of renal function, prolongation of dose interval should be considered; pefloxacin should be avoided in severe impairment of renal function.
Ma
L
L
Henan Provincial People's Hospital, Zhengzhou 450003, China.
Sun
C
C
Wu
J
J
D000368:Aged; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007668:Kidney / Q000187:drug effects / Q000503:physiopathology; D008297:Male; D015366:Pefloxacin / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D011014:Pneumonia / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism / Q000503:physiopathology; D051437:Renal Insufficiency / Q000150:complications / Q000503:physiopathology*; D013183:Sputum / Q000378:metabolism*; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D015366:Pefloxacin